Literature DB >> 21544030

Prolonged xenograft survival induced by inducible costimulator-Ig is associated with increased forkhead box P3(+) cells.

Russell Hodgson1, Dale Christiansen, Andrew Ziolkowski, Effie Mouhtouris, Charmaine J Simeonovic, Francesco L Ierino, Mauro S Sandrin.   

Abstract

BACKGROUND: Blockade of the inducible costimulator (ICOS) pathway has been shown to prolong allograft survival; however, its utility in xenotransplantation is unknown. We hypothesize that local expression of ICOS-Ig by the xenograft will suppress the T-cell response resulting in significant prolonged graft survival.
METHODS: Pig iliac artery endothelial cells (PIEC) secreting ICOS-Ig were generated and examined for the following: (1) inhibition of allogeneic and xenogeneic proliferation of primed T cells in vitro and (2) prolongation of xenograft survival in vivo. Grafts were examined for Tregs by flow cytometry and cytokine levels determined by quantitative reverse-transcriptase polymerase chain reaction.
RESULTS: Soluble ICOS-Ig markedly decreased allogeneic and xenogeneic primed T-cell proliferation in a dose-dependent manner. PIEC-ICOS-Ig grafts were significantly prolonged compared with wild-type grafts (median survival, 34 and 12 days, respectively) with 20% of PIEC-ICOS-Ig grafts surviving more than 170 days. Histological examination showed a perigraft cellular accumulation of Forkhead box P3 (Foxp3(+)) cells in the PIEC-ICOS-Ig grafts, these were also shown to be CD3(+)CD4(+)CD25(+). Survival of wild-type PIEC grafts in a recipient simultaneously transplanted with PIEC-ICOS-Ig were also prolonged, with a similar accumulation of Foxp3(+) cells at the periphery of the graft demonstrating ICOS-Ig induces systemic graft prolongation. However, this prolongation was specific for the priming xenograft. Intragraft cytokine analysis showed an increase in interleukin-10 levels, suggesting a potential role in induction/function of CD4(+)CD25(+)Foxp3(+) cells.
CONCLUSIONS: This study demonstrates prolonged xenograft survival by local expression of ICOS-Ig, we propose that the accumulation of CD4(+)CD25(+)Foxp3(+) cells at the periphery of the graft and secretion of interleukin-10 is responsible for this novel observation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21544030     DOI: 10.1097/TP.0b013e31821774e0

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

Review 1.  Current progress in xenogeneic tolerance.

Authors:  Kazuhiko Yamada; Joseph Scalea
Journal:  Curr Opin Organ Transplant       Date:  2012-04       Impact factor: 2.640

Review 2.  Immunological challenges and therapies in xenotransplantation.

Authors:  Marta Vadori; Emanuele Cozzi
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

Review 3.  Potential targeting of B7-H4 for the treatment of cancer.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 4.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

5.  CD28 family and chronic rejection: "to belatacept...And beyond!".

Authors:  Marcos V Silva; Juliana R Machado; Laura P Rocha; Lúcio R Castellano; Marlene A Reis; Rosana R M Corrêa
Journal:  J Transplant       Date:  2012-06-07

6.  ICOS regulates the generation and function of human CD4+ Treg in a CTLA-4 dependent manner.

Authors:  Jian Zheng; Ping-Lung Chan; Yinping Liu; Gang Qin; Zheng Xiang; Kwok-Tai Lam; David B Lewis; Yu-Lung Lau; Wenwei Tu
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.